A Phase 1 Study to Examine the Effect of Renvela on the P... | NCT02346890

Studies
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

NCT02346890

Sponsor

Ardelyx

Status

Completed

Last Update Posted

Jan 27, 2015Estimated

Enrollment

16Actual

Phase

Phase 1

Conditions

Healthy

Interventions

AZD1722
Renvela

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2015

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Apr 2013

Primary Completion Date

Apr 2013Actual

Completion Date

Apr 2013Actual

First Submitted Date

Sep 24, 2014

First Submission Date that Met QC Criteria

Jan 26, 2015

First Posted Date

Jan 27, 2015Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 26, 2015

Last Update Posted Date

Jan 27, 2015Estimated

Name	Class
AstraZeneca	INDUSTRY

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

16Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
AZD1722 alone	Experimental	15 mg BID	Drug: AZD1722
AD1722 with Renvela	Experimental	AZD1722 15 mg BID and Renvela 800 mg TID	Drug: AZD1722 Drug: Renvela

Interventions

Name	Type	Description	Arm Group Labels	Other Names
AZD1722	Drug		AD1722 with Renvela AZD1722 alone	RDX5791 Tenapanor

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Sodium levels in stool and urine	Pharmacodynamic activity	4 days

Secondary Outcomes

Measure	Description	Time Frame
Evaluate the safety of AZD1722, measured by Adverse events	Adverse events	8 days
Evaluate the safety of AZD1722, measured by clinical laboratory changes	clinical laboratory changes

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Healthy man or woman
Body mass index between 18 and 29.9 kg/m2

Exclusion Criteria:

Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract
Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

19 Years

Maximum Age

65 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
David P Rosenbaum, Ph.D.	Ardelyx, Inc.	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Healthcare Discoveries, LLC		San Antonio	Texas	78209	United States

Intervention Browse Module

MeSH Terms

ID	Term
C000599417	tenapanor
D000069603	Sevelamer

Ancestor Terms

ID	Term
D011073	Polyamines
D000588	Amines
D009930	Organic Chemicals

Browse Leaves

Not provided

Browse Branches

Not provided